Reduced Plasma Levels of Very-Long-Chain Dicarboxylic Acid 28:4 in Italian and Brazilian Colorectal Cancer Patient Cohorts

Author(s):Show less -

Wood, Paul L. ^[1] ; Donohue, Michelle M. ^[1] ; Cebak, John E. ^{[1, 2]} ; Beckmann, Taylor G. ^[2] ; Fernandes Messias, Marcia Cristina ^[3] ; Credidio, Laura ^[4] ; Rodrigues Coy, Claudio Saddy ^[4] ; Carvalho, Patricia de Oliveira ^[3] ; Crotti, Sara ^[5] ; D'Aronco, Sara ^{[5, 6]} ; Urso, Emanuele D. L. ^[6] ; Agostini, Marco ^{[5, 6]}

Affiliation

^[1] Lincoln Mem Univ, Coll Vet Med, Metabol Unit, 6965 Cumberland Gap Pkwy, Harrogate, TN 37752 - USA

^[2] Lincoln Mem Univ, Dept Med, DeBusk Coll Osteopath Med, 6965 Cumberland Gap Pkwy, Harrogate, TN 37752 - USA

^[3] Sao Francisco Univ USF, Lab Multidisciplinary Res, BR-12916900 Sao Paulo - Brazil

^[4] Univ Estadual Campinas, Dept Surg, UNICAMP, BR-12916900 Sao Paulo - Brazil

^[5] Ist Ric Pediatr Citta Speranza, Nanoinspired Biomed Lab, I-35127 Padua - Italy

^[6] Univ Padua, Dept Surg Oncol & Gastroenterol Sci, Surg Clin 1, I-35128 Padua - Italy

• Document type: Journal article
• Source: METABOLITES; v. 8, n. 4 DEC 2018.
• Web of Science Citations: 1

Abstract

Background: There are currently no blood-based biomarkers for early diagnosis of colorectal cancer. Previous research has suggested that very-long-chain dicarboxylic acid (VLCDCA) 28:4 might be such a biomarker. Methods: Using high-resolution mass spectrometry, we analyzed VLCDCA 28:4 in the plasma of colorectal cancer patients in Italian {[}n = 62] and Brazilian {[}n = 52] cohorts. Additionally, we investigated individuals diagnosed with familial adenomatous polyposis (FAP; n = 27), one of the most important clinical forms of inherited susceptibility to colorectal cancer. Results: Decrements in plasma levels of VLCDCA 28:4 were monitored in colorectal cancer patients. These decreases were independent of the stage of tumor development and the individual's age. However, no decrements in VLCDCA 28:4 were monitored in FAP patients. Conclusions: The plasma levels of VLCDCA 28:4 represent a potential biomarker of sporadic colorectal cancer. In addition, it is possible that resupply of this anti-inflammatory lipid may represent a new therapeutic strategy for CRC and inflammatory disorders. (AU)

• FAPESP's process: 16/11905-2 - Lipidomic analysis of cancer patients blood in the search for possible circulatory biomarkers
• Grantee: Patrícia de Oliveira Carvalho
• Support Opportunities: Regular Research Grants